Search

Search Constraints

You searched for: Author/Creator Luthman, Johan

Search Results

1. O4‐12‐05: EVALUATION OF TAU DEPOSITION IN AMYLOID‐POSITIVE MCI OR MILD AD DEMENTIA SUBJECTS FROM THE ELENBECESTAT MISSION AD PROGRAM USING [18 F]PI‐2620 PET. (1st July 2019)

2. P4‐242: A case‐control cohort study to define a threshold for the tau/abeta42 ratio in cerebrospinal fluid optimized for diagnosis of Alzheimer's disease. (1st July 2015)

3. P4‐075: LUMIPULSE® G TOTAL TAU TO β‐AMYLOID 1‐42 RATIO CUT‐POINT DETERMINATION FOR AMYLOID ELIGIBILITY SCREENING. (1st July 2006)

4. O1‐12‐06: PHASE 1 MULTIPLE ASCENDING DOSE (MAD) STUDY OF PHOSPHODIESTERASE‐9 INHIBITOR E2027: CONFIRMATION OF TARGET ENGAGEMENT AND SELECTION OF PHASE 2 DOSE IN DEMENTIA WITH LEWY BODIES. (1st July 2006)

6. DT‐01‐07: TREATMENT OF EARLY AD SUBJECTS WITH BAN2401, AN ANTI‐Aβ PROTOFIBRIL MONOCLONAL ANTIBODY, SIGNIFICANTLY CLEARS AMYLOID PLAQUE AND REDUCES CLINICAL DECLINE. (1st July 2006)

7. IC‐P‐040: EVALUATION OF TAU DEPOSITION IN AMYLOID POSITIVE MCI OR MILD‐AD DEMENTIA SUBJECTS FROM THE ELENBECESTAT MISSION AD PROGRAM USING [18 F]PI‐2620 PET. (1st July 2019)

9. Blood‐based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. Issue 1 (18th November 2016)

10. 2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. Issue 6 (1st June 2015)